Human influenza viruses passaged in eggs often acquire mutations in the hemagglutinin (HA) 39 receptor binding site (RBS). To determine if egg-adapted H1N1 vaccines commonly elicit 40 antibodies targeting the egg-adapted RBS of HA, we completed hemagglutinin-inhibition assays 41 with A/California/7/2009 HA and egg-adapted A/California/7/2009-X-179A HA using sera 42 collected from 159 humans vaccinated with seasonal influenza vaccines during the 2015-16 43 season. We found that ~5% of participants had ≥4-fold higher antibody titers to the egg-adapted 44 viral strain compared to wild type viral strain. We used reverse-genetics to demonstrate that a 45 single egg-adapted HA RBS mutation (Q226R) was responsible for this phenotype. 46 47 48
50
Introduction 51 Influenza viruses attach to cells through specific interactions between the viral 52 hemagglutinin (HA) protein and terminally-linked sialic acids on target cells. Human influenza 53 viruses possess a conserved HA receptor binding site (RBS) that interacts efficiently with α-2,6-54 linked sialic acids, whereas the HA RBS of avian influenza strains primarily interacts with α-2,3-55 linked sialic acids [1] . Most human influenza vaccine antigens are prepared from viruses grown 56 in fertilized chicken eggs. Human influenza viruses grown in eggs often acquire mutations in or 57 near the HA RBS that increase binding to α-2,3-linked sialic acids, and some of these mutations 58 lead to large antigenic changes [2] . For example, the 2016-17 H3N2 egg-grown vaccine was 59 antigenically mismatched compared to circulating H3N2 strains due to a T160K HA mutation 60 that arose during egg passage [3] . In this case, the egg-adapted T160K HA mutation was 61 located in a classic antigenic site adjacent to the RBS [3] .
62
Recent studies have identified antibodies with long CDR3 domains that essentially act 63 like sialic acid mimics that make physical contact with HA RBS residues [4, 5]. There is 64 considerable interest in developing vaccines that elicit these types of antibodies since they are 65 able to neutralize a wide range of different influenza virus strains. It is unclear if vaccine strains 66 with egg-adapted RBSs are able to elicit these broadly reactive antibodies, given that most egg-67 grown vaccine strains possess RBS mutations that facilitate growth in eggs. In a landmark 68 study, Raymond and colleagues isolated monoclonal antibodies from vaccinated humans that 69 bind to the egg-adapted RBS of H1N1 but not to circulating H1N1 viral strains [6]. These 70 antibodies bind to egg-grown H1N1 viral strains that utilize α-2,3-linked sialic acids but not to 71 viral strains that actually circulate in humans that utilize α-2,6-linked sialic acids [6] . It is 72 unknown if these types of antibodies are commonly elicited by egg-adapted H1N1 vaccine 73 strains. To address this, we completed hemagglutination-inhibition (HAI) assays with 'wild-type' 
91
HAI assays were performed using de-identified sera collected pre-and post-vaccination 92 from 159 individuals with the approval of the University of Pennsylvania Institutional Review
93
Board. Sera were pre-treated with receptor-destroying enzyme for 2 hours at 37°C and 94 inactivated for 30 minutes at 55°C. Sera were also absorbed with 10% red blood cell solution 95 for 1 hour at 4°C prior to completing HAI assay. We used influenza virus-like particles (VLPs) 96 for the HAI assays in this study as previously described [9], since it is difficult to grow human 97 H1N1 viruses without adaptive mutations. We used VLPs that expressed the 'wild-type'
98
A/California/7/2009 H1N1 HA or the egg-adapted A/California/7/2009-X-179A H1N1 HA. The
99
VLPs for these experiments possessed a neuraminidase (A/duck/Alberta/300/77) that most 100 5 humans have not been exposed to previously. We constructed our VLPs in this manner to 101 avoid potential complications from neuraminidase-reactive antibodies. We also included 20nM 102 of oseltamavir in our HAI assays to prevent neuraminidase binding of red blood cells [10]. The
103
A/California/7/2009 wild-type HA and the A/California/7/2009-X-179A HA in our VLP constructs 104 differ at 2 residues; the X-179A strain possesses a glutamine to arginine mutation at position 105 226 (Q226R) and from lysine to threonine at position 212 (K212T). For some experiments we 106 completed additional HAI assays using VLPs that expressed A/California/7/2009 HAs that were 107 engineered to possess only the Q226R mutation that is in the RBS.
109

Results
110
We completed two independent HAI assays using sera from 159 individuals collected 111 prior to and ≥14 days after vaccination. Vaccinated subjects ranged in age from 13 to 76 years Supplemental Table 1 .
119
We identified 8 participants (~5% of participants that we tested) that had antibody titers 120 that were ≥4-fold higher to the egg-adapted X-179A HA compared to the wild-type HA following 121 vaccination in 2 independent HAI experiments (Supplemental Table 1 ). Some of these 122 individuals possessed antibodies that reacted to the X-179A HA better than the WT HA prior to 123 vaccination, which is likely the case because the X-179A vaccine strain has been utilized in the 124 human population since 2009. However, some individuals clearly seroconverted against the X-6 HAI titer against X-179A HA rose from a value of 15 pre-vaccination to a value of 100 post-127 vaccination but HAI titers in this individual against WT HA were nearly the same pre-and post-128 vaccination (pre-vaccination titer of 10 and post-vaccination titer of 25) (Supplemental Table 1; 129 average HAI titer from 2 experiments described in text). Similarly, participant #147 was HAI 130 negative against both HAs prior to vaccination and had a much higher HAI titer against X-179A
131
HA (HAI titer of 70) compared to WT HA (HAI titer of 10) following vaccination (Supplemental 132 Table 1 ; average HAI titer from 2 experiments described in text). These data indicate that the 133 X-179A egg-adapted vaccine strain elicits and/or reinforces antibody responses that recognize 134 the X-179A egg-adapted H1N1 HA more efficiently than the WT H1N1 HA in some individuals.
135
To confirm that the difference in WT HA versus X-179A HA reactivity was due to RBS 136 differences, we completed additional HAI experiments using A/California/7/2009 HAs that were 137 engineered to possess only the Q226R RBS HA mutation. HAI titers were lower using the WT 138 HA compared to the HA with the Q226R mutation ( Figure 2) , indicating that the 8 individuals 139 that we identified in our study possessed antibodies that targeted the egg-adapted RBS of the 140 X-179A H1N1 vaccine strain.
141
Seven out of the 159 vaccinated individuals in this study had PCR-confirmed H1N1 142 infection during the course of the 2015-16 season. All 7 of these individuals possessed low 143 antibody titers against the WT H1N1 strain after vaccination (Supplemental Table 1 ).
144
Importantly, one of the H1N1-infected participants (#131) had a higher HAI titer to the X-179A 145 HA compared to the WT HA following vaccination, albeit titers to both HAs were low in this 146 individual. From these studies, we conclude that some individuals vaccinated with the egg-147 adapted X-179A vaccine strain produce antibodies that recognize egg-adapted epitopes in the 148 HA RBS and we speculate that this might contribute to reduced vaccine effectiveness. 
166
We found that ~5% of individuals vaccinated with the 2015-2016 seasonal influenza 167 vaccine possessed antibodies that recognized the X-179A H1N1 HA ≥4-fold more efficiently 168 compared to the WT H1N1 HA. Given that >140 million people receive a seasonal influenza 169 vaccine in the U.S. each year [12], these data indicate that a large number of individuals (>7 170 million!) possess antibodies that preferentially recognize the egg-adapted HA RBS of H1N1 171 rather than the HA of H1N1 viruses that circulate in humans. For our study, we focused on 172 individuals that had ≥4-fold differences in HAI titers using the different HAs, and this 173 conservative fold difference cutoff likely underestimates the number of individuals that possess 174 antibodies that bind to the egg-adapted H1N1 strain but not the circulating H1N1 strain. It is 175 notable that participants in our study come from a population with historically high annual 176 vaccine uptake rates, and therefore they are likely to have had multiple previous influenza 
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While most studies of egg-adaptation have focused on H3N2 viruses, our study clearly 185 demonstrates that egg-adaptations in the HA RBS of H1N1 viruses can also be problematic. 
